Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Sanofi Goes East to Find Growth

There must be something about Eastern Europe that gets drugmakers excited. Last week, Sanofi-Aventis (NYSE: SNY  ) announced that it has outbid a rival for Czech generic-drug maker Zentiva.

A Dutch financial group had already made an offer to purchase the company, but Sanofi, already a large Zentiva shareholder, has so far trumped this bid with its $2.6 billion offer for Zentiva.

Sanofi's potential purchase of Zentiva would significantly expand its generic-drug operations. Other top pharmaceutical firms like Novartis (NYSE: NVS  ) have extensive generic-drug operations as well, and if Sanofi can snag Zentiva, it could better compete against these rivals, as well as the other, more traditional generic-drug manufacturers.

With billions of dollars in patented drugs losing their marketing exclusivity in the coming years, generic-drug makers operating in the right part of the world can sometimes be hot commodities. Zentiva, for instance, isn't the only Eastern European drugmaker to get caught up in a bidding war in recent years. In 2006, Barr Pharmaceuticals (NYSE: BRL  ) won a lengthy bidding contest for Croatia-based Pliva.

Last year, Zentiva had sales of nearly $1.1 billion at current exchange rates. Much of Zentiva's operations are located in fast-growing Eastern European countries like Poland and Hungary, as well as places outside of the European Union, such as Turkey.

Sanofi's bid currently bests PPF's rival Zentiva offer by 10.5%, although there are no indications that the bidding war is necessarily over. While the generic-drug business is generally thought of as a low-margin, ultra-competitive environment, there is still a lot of room to compete geographically. As Eastern Europe's economies expand, they have been a strong growth provider for generic-drug makers. Sanofi seems to have noticed.

This Foolishness is far from generic:

Barr Pharmaceuticals is an active Stock Advisor pick. Click here to start a 30-day risk-free trial of the newsletter and see all the Gardner brothers' current recommendations.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 670389, ~/Articles/ArticleHandler.aspx, 10/23/2016 8:30:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:02 PM
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****
BRL.DL $65.80 Down +0.00 +0.00%
Barr Pharmaceutica… CAPS Rating: ****
NVS $75.54 Down -0.38 -0.50%
Novartis CAPS Rating: ****